Beerenberg AS (OSL:BBERG)

Inozyme Pharma Revenue

Beerenberg AS had revenue of 802.00M NOK in the quarter ending September 30, 2024, with 38.51% growth. This brings the company's revenue in the last twelve months to 2.86B, up 24.29% year-over-year. In the year 2023, Beerenberg AS had annual revenue of 2.34B with 5.46% growth.

• Revenue (ttm): 2.86B
• Revenue Growth: +24.29%
• P/S Ratio: 0.35
• Revenue / Employee: 1.76M
• Employees: 1,432
• Market Cap: 1.01B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	2.34B	121.23M	5.46%
Dec 31, 2022	2.22B	93.44M	4.39%
Dec 31, 2021	2.13B	431.33M	25.42%
Dec 31, 2020	1.70B	-512.33M	-23.19%
Dec 31, 2019	2.21B	690.19M	45.43%